8-KLeadership Changes

JOHNSON & JOHNSON 8-K Report, Executive Changes (Mar 2, 2007)

Filed March 2, 2007For Securities:JNJ

Summary

Johnson & Johnson (JNJ) filed an 8-K on March 2, 2007, reporting the retirement of two key executives: Mr. Robert J. Darretta, Vice Chairman of the Board of Directors and former Chief Financial Officer, and Dr. Per A. Peterson, Chairman of the Research & Development Pharmaceuticals Group. Both retirements were as previously planned and announced by the company, indicating a smooth transition in leadership. While this filing primarily reports on executive departures, it's important for investors to note that these changes were anticipated. The company has a history of structured succession planning, and these departures, while significant, are not presented as unexpected events. Investors should monitor subsequent filings for information regarding the appointment of successors and any potential impact on the company's strategic direction and financial operations.

Key Highlights

  • 1Reporting of executive departures: Mr. Robert J. Darretta and Dr. Per A. Peterson have retired.
  • 2Mr. Darretta held significant roles as Vice Chairman of the Board, Director, former CFO, and Executive Committee member.
  • 3Dr. Peterson was Chairman of the Research & Development Pharmaceuticals Group and an Executive Committee member.
  • 4Both retirements were planned and previously announced by the company.
  • 5The filing was made on March 2, 2007, with the earliest event reported on February 28, 2007.
  • 6This 8-K filing is routine and confirms planned leadership transitions.

Frequently Asked Questions

The main purpose of this 8-K filing is to formally report the planned and previously announced retirements of two key executives: Mr. Robert J. Darretta and Dr. Per A. Peterson.

No, the filing explicitly states that both retirements were 'as previously planned and announced by the Company,' suggesting they were not unexpected events for investors who had been following company communications.

Mr. Robert J. Darretta was Vice Chairman of the Board of Directors, a Director, former Chief Financial Officer, and an Executive Committee member. Dr. Per A. Peterson was the Chairman of the Research & Development Pharmaceuticals Group and an Executive Committee member.

Investors should monitor subsequent SEC filings for announcements regarding the appointment of successors to Mr. Darretta and Dr. Peterson, and to understand how these leadership changes might influence the company's future strategic decisions and operational execution.